Introduction {#s1}
============

Pain and distress symptoms are among the most challenging clinical problems faced by those caring for children with severe neurological impairment (SNI). Up to 50% of children with severe cognitive impairment are reported to have pain episodes every week.[@R1] Even in the context of an apparent gastrointestinal source, the underlying cause for pain and irritability often remains unclear.[@R2] Both central neuropathic pain and visceral hyperalgesia, an increased response and sensitivity to stimuli within the gastrointestinal tract,[@R3] are potential causes of this pain and irritability.[@R4]

In a study published over a decade ago, Hauer *et al* first identified the potential benefits of gabapentin in nine children with SNI[@R4] and a follow-up study by the same author identified an improvement in pain behaviours in over 90% of 22 children treated with gabapentin.[@R5] We performed a retrospective study in 42 patients, to see if the findings of Hauer's seminal studies[@R4] could be replicated, and to investigate if pregabalin is an appropriate second-line agent for this indication.

Methods {#s2}
=======

A retrospective chart review of paediatric patients with SNI attending the gastroenterology and palliative care services at Our Lady's Children's Hospital, Crumlin was performed. All patients who had been prescribed gabapentin treatment for pain or irritability of unknown origin were included. Information was gathered from medical notes. Prior to commencing gabapentin all children in this study were formally clinically evaluated by the paediatric gastroenterology or palliative care services, and investigated or treated empirically for organic disease, without improvement of their symptoms. The rationale for using gabapentin or pregabalin in these children with possible visceral hyperalgesia was based on its role in reducing neuropathic pain as well as its central effects.[@R6]

Patients were not involved in the design or the conduction of this research.

Results {#s3}
=======

There were 42 patients included in the study, with follow-up ranging from 3 to 63 months and a mean duration of 21 months---a total of 75 patient-years' follow-up. The most frequently reported symptoms prior to commencement of gabapentin were crying and irritability, occurring in 39 and 37 children, respectively. A good or very good overall response to gabapentin was reported in 25 patients, while minimal or no response occurred in eight and seven patients, respectively. Improvement in irritability was reported in 30 patients, and 17 patients required less pain medication ([table 1](#T1){ref-type="table"}). Increased lethargy was reported in three cases and there were isolated cases of vomiting, alopecia, twitching and raised liver enzyme levels. There was an apparent loss of response over time in four children ([table 1](#T1){ref-type="table"}). The mean duration of gabapentin treatment in those four children was 25 months. All were on the highest dose of 60 mg/kg/day.

###### 

Effectiveness of gabapentin

                                    n    \%
  --------------------------------- ---- ----
  Overall response to gabapentin         
   Deteriorated                     1    2
   None                             8    19
   Minimal                          7    17
   Good                             10   24
   Very good                        15   36
   Not documented                   1    2
  Change in irritability                 
   Yes                              30   71
   No                               11   26
   Not documented                   1    2
  Pain reduction                         
   Yes                              17   40
   No                               23   55
   Not documented                   2    5
  Adverse effects                        
   None                             31   74
   Improvement reducing over time   4    10
   Lethargy                         3    7
   Twitching                        1    2
   Alopecia                         1    2
   Vomiting                         1    2
   Elevated liver enzymes           1    2
   Gabapentin discontinued          15   36
  Of them                                
   Alopecia                         1    7
   Asymptomatic                     1    7
   No improvement                   1    7
   Changed to pregabalin            12   80

Gabapentin was switched to pregabalin as a second-line agent in 12 of the 42 children. The dose of gabapentin was maximised prior to switching in 11 of the children. There was no noted effect of pregabalin in two patients, minimal in six, good in three and not documented in one ([table 2](#T2){ref-type="table"}). The mean duration of follow-up of patients on pregabalin was 13.5 months.

###### 

Pregabalin

                                       n    \%
  ------------------------------------ ---- ----
  Total switch to pregabalin           12   
  Rationale for change to pregabalin        
   Lethargy                            2    17
   Ongoing symptoms                    6    50
   Elevated liver enzymes              1    8
   Improvement reducing over time      3    25
  Efficacy of pregabalin                    
   Deteriorated                        0    0
   None                                2    17
   Minimal                             6    50
   Good                                3    25
   Very good                           0    0
   Not documented                      1    8

Discussion {#s4}
==========

Acknowledging the limitations surrounding the retrospective nature of this study, it nevertheless serves to corroborate the observations of Hauer *et al* [@R4] and more than doubles the numbers of reported children with SNI receiving gabapentin. It suggests a possible role for pregabalin where gabapentin fails or is not tolerated. Perhaps more importantly, it provides evidence for the efficacy of these medications in a very challenging and growing cohort of children where there otherwise exist extremely limited therapeutic options.
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